Get the Stockscreener App
1.52
3.80%
-0.06
After Hours:
1.51
-0.01
-0.66%
Pliant Therapeutics Inc stock is traded at $1.52, with a volume of 1.07M.
It is down -3.80% in the last 24 hours and down -53.80% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.58
Open:
$1.59
24h Volume:
1.07M
Relative Volume:
0.57
Market Cap:
$93.08M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4919
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
-3.80%
1M Performance:
-53.80%
6M Performance:
-87.33%
1Y Performance:
-90.12%
1-Day Range:
$1.50
$1.61
1-Week Range:
$1.38
$1.68
52-Week Range:
$1.26
$16.52
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.52 | 93.08M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - Bluefield Daily Telegraph
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Needham Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq
If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register
Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Cut to Market Perform at Leerink Partners - MarketBeat
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire
Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga India
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks
Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN
Pliant stock downgraded at Stifel trial discontinuation (PLRX:NASDAQ) - Seeking Alpha
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32 - Marketscreener.com
Needham Downgrades Pliant Therapeutics to Hold From Buy -March 04, 2025 at 08:28 am EST - Marketscreener.com
Pliant Therapeutics: Hold Rating Maintained Amid Trial Discontinuation and Adjusted Financial Outlook - TipRanks
RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Pliant Therapeutics Reports Q4 2024 Results and Updates - MSN
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral By Investing.com - Investing.com Canada
Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral - Investing.com India
Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization - TipRanks
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating - Investing.com India
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating By Investing.com - Investing.com UK
Pliant Therapeutics (NASDAQ:PLRX) Lowered to “Hold” Rating by Stifel Nicolaus - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - GlobeNewswire
Pliant Therapeutics shares rise on better-than-expected Q4 earnings - Investing.com
Pliant Therapeutics shares rise on better-than-expected Q4 earnings By Investing.com - Investing.com Australia
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results - GlobeNewswire
Pliant's IPF Trial Halted on Safety Concerns: What's Next for Their $357M Pipeline? - StockTitan
Stifel cuts Pliant Therapeutics stock rating to hold, target to $3 By Investing.com - Investing.com South Africa
Pliant ends late-stage pulmonary fibrosis trial amid safety concerns - FirstWord Pharma
Leerink cuts Pliant Therapeutics stock rating after trial halt - Investing.com India
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder - Benzinga India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
Leerink downgrades Pliant Therapeutics after trial discontinuation - TipRanks
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):